@Q32Bio

Clinical-stage biotechnology company focused on developing innovative therapies for alopecia areata and other autoimmune and inflammatory diseases.

 830 Winter Street, Waltham, MA
Joined May 2020
  • Tweets190
  • Following32
  • Followers255
164Media
Q32 Bio Inc. retweeted
Citeline@Citeline13 Sep 2024
The Scrip Awards shortlist has now been announced! 📢Visit our website to see who the 2024 finalists are! #ScripAwards ow.ly/VCTQ50Tl0mG
1
3
3
6
1,938
Shoutout to @Xiliotx and @Q32Bio for supporting Enroot, an @LS_Cares nonprofit partner! These two LSC corporate partners teamed up to provide 40 camping gear kits for @Enrooteducation students' camping trip in the White Mountains. 🎒⛺ #LifeScienceCares #NetworkOfGood
3
7
776
Q32 Bio Inc. retweeted
Endpoints News
@endpts9 Mar 2021
Intercept CMO Jason Campagna is jumping to Q32 Bio, joining CEO Mike Broxson’s team in Cambridge, MA as they explore the next generation of complement drugs. endpts.com/exclusive-former-…

Exclusive: Former Intercept CMO lands new gig at Q32 Bio, two weeks after leaving the NASH biotech

Just two weeks ago, Intercept CMO Jason Campagna followed the biotech’s founding CEO out the door to pursue other opportunities, per an SEC filing, as analysts sense a major ...

endpoints.news
5
6
Portfolio News: @q32bio closes $60M Series B financing to advance therapeutics designed to restore immune homeostasis; also announces first patient dosed in Phase 1 clinical trial evaluating IL-7R antibody ADX-914 bit.ly/31TraPU
1
3
As Q32 learns more about the drug, it will narrow down where it wants to go in phase 2. fiercebiotech.com/biotech/q3…

Q32 Bio banks $60M as it ramps up 'immune rebalancing' programs

Just five months after coming out of stealth, Q32 Bio is back for round two. | Just five months after coming out of stealth, Q32 Bio is back for round two. The autoimmune player raised $60 million...

fiercebiotech.com
2
1
2
Q32 Bio Inc. retweeted
Endpoints News
@endpts29 Oct 2020
Q32 Bio grabs $60M to kick off human studies for next-gen complement drugs — with some Covid-19 tweaks along the way endpts.com/q32-bio-grabs-60m…

Q32 Bio grabs $60M to kick off human studies for next-gen complement drugs — with some Covid-19...

For a company that launched in the early months of the pandemic, Q32 Bio had its fair share of run-ins with the new normals under Covid-19. The original plan, for ...

endpoints.news
1
3
8
When the pandemic hit, the team at @Q32Bio stepped up by raising money, donating supplies and volunteering virtually through LSC’s COVID-19 Response Fund. Today we’re proud to welcome CEO Mike Broxson and CoFounder/CSO Shelia Violette to our Board of Advisors! #LSCImpact
1
1
7
Fundamentally, we aim to restore homeostasis to adaptive and innate immunity. We’re getting the immune response back in check rather than ablating pathways or cell types,” said Q32 CEO Michael Broxson fiercebiotech.com/biotech/q3…
1
2
1
2
Q32 Bio Inc. retweeted
STAT
@statnews27 May 2020
Q32 Bio aims to address problems with both innate immunity, the body’s initial response to an invader, and adaptive immunity, which develops antibodies to the foreign interloper.  buff.ly/2XxAdDb
3
7
Startup Spotlight: Going after immune regulators when they cause disease statnews.com/2020/05/27/star…

Startup Spotlight: Going after immune regulators when they cause disease instead of prevent it

Q32 Bio aims to address problems with both innate immunity, the body’s initial response to an invader, and adaptive immunity, which develops antibodies to the foreign interloper. 

statnews.com
2
1
6
Meet @Q32Bio, its stellar team, and its exciting platform & pipeline: q32bio.com/

Q32 Bio

Q32 Bio is developing drugs targeting powerful regulators of both the innate and adaptive immune systems with the goal of re-balancing the immune system.

q32bio.com
Q32 Bio Inc.@Q32Bio27 May 2020
Today we’re thrilled to announce our official launch. Check out our pipeline focused on both innate and adaptive immune system-based therapies and learn more about our plans to enter the clinic this year. q32bio.com/q32bio-launches-n…

Q32 Bio Launches to Develop Novel Therapeutics Targeting Regulators of Innate and Adaptive Immunity...

Proprietary tissue-targeted complement platform and best-in-class IL-7R antibody technology to treat patients with severe autoimmune and inflammatory disease; clinical trials begin in 2020

q32bio.com
2
3
15
Q32 Bio Inc. retweeted
Endpoints News
@endpts27 May 2020
For a post-Soliris world, Atlas-backed Q32 Bio outlines $46M next-gen complement play endpts.com/in-a-post-soliris…

For a post-Soliris world, Atlas-backed Q32 Bio outlines $46M next-gen complement play

Long before Alexion kindled a renaissance of complement therapeutics with the introduction of the first anti-C5 antibody, Mike Holers — a longtime professor at the University of Colorado School of...

endpoints.news
3
3
13
Load more